MCQ-2558 part 2

7/24/2019 MCQ-2558 part 2

1/14

MCQ12 : 1/2558 (15 2558) Rx71

MCQ12 : 1/2558

Case: . . . Omeprazole

. .

1. Omeprazole

1.2.3.

4.5.

xx . .

G 256/2553 . 11-... (

13 )

6. 1. 2. 3.4.5.

12. 1.2.3.4.5.

Case 1:

24 2 Amoxycillin 1

1. 1. Candida albicans2. Trichomonas vaginalis3. Gardnerella vaginalis4. Clamydia trachomatis

5. Neiseria gonorrhea

2. 1. 2. 3.

4.

5.

3. 1. Metronidazole2. Clotrimazole3. Azithromycin4. cefixime

5. Norfloxacin

1

7/24/2019 MCQ-2558 part 2

2/14

MCQ12 : 1/2558 (15 2558) Rx71

fluconazole

4. fluconazole

1.

2.3.

4. 7 5.

5. Fluconazole strong CYP inhibitor CYP1. 1A22. 2C93. 2E64. 1E25. 2D6

6. fluconazole1. 2. 3. 4. DNA5. Mitotic spindle

7. Clotrimazole

0.1 / 1 PEG 2.5 PEG Base DV = 1 ( PEG = 1.2

Theobroma oil)1. 2.002. 2.403. 2.384. 2.425.

2.50

Case 2:

2

Toxic epidermal necrolyisis with secondarybacterial infection (ICU) Cloxacillin 2g IV stat

6 Glibenclamide2 Enalapril1 Allopurinol(100) 1x1 pc2 1 1

1. Toxic epidermalnecrolyisis

1.

Allopurinol

2. Glibenclamide3. Enalapril4. S. aureus5.

2. Toxic epidermal necrolyisis

1.

2. 30%

3. TEN 4. 2

5. 1

2

7/24/2019 MCQ-2558 part 2

3/14

MCQ12 : 1/2558 (15 2558) Rx71

3. cloxacillin

1.

2.

.3.

cloxacillin 4.

5.

IV infusion 30-60

4. NCCMERP

1. A2. B3. C4. F5. I

5. 1. Type I2. Type II3. Type III4. Type IV5. Mixed type

6.

1. Acacia2. Bentonite3. Alginate4. Gelatin5. Pectin

7. hydrophilic colloid polymer

1. Carageenan2. Chitosan

3.

Gelatin B

4. Tragacanth5. Veegum

8. sulfonamide antibiotic ()

1.2.

3.

Allopurinol

4.

Cloxacillin

5.

Hydrochlorothiazide

3

7/24/2019 MCQ-2558 part 2

4/14

MCQ12 : 1/2558 (15 2558) Rx71

Case 3:

70 CXR : Hyperinflation and left lower lung

pneumonia

: 25 20 5

oxygen tiotropium

ipratopium/fenoterol prn

Formoterol/Salmeterol 2 -

T 38.5 C RR 32 /FEV 40%

1.1. Hyperinflation COPD2. Pneumonia exacebation3. FEV1 < 40%

severe

4.

Methacholine test5. pack-year 40

2.

1.2. Formoterol3. Salbutamol

4.

Tiotropium

5. Budesonide

3. 1. (CXR ...infiltration??)2. 3. 4. 5.

4. 1. influenza vaccine 5 2. Salmeterol/fluticasone

3.

Montelukast

4. Prednisolone5. Roxithromycin

5. Prednisolone 5 mg 2x2 pc

1. 5 2. 21

3.

28 10%4. 30 10%5.

6. aerosol alcohol dosage form Isoproterenol sulfate 33 g

Oleyl alcohol 33 g

Ascorbic acid 3.3 gMyristyl alcohol 33.3 g

1. Emulsions2. Solutions3. Suspensions4. Powders5. Liposome Nanoparticle

7. DPI1. Dry powder2. propellant3. Dry powder lactose carrier4. Expiratory volume

5.

4

7/24/2019 MCQ-2558 part 2

5/14

MCQ12 : 1/2558 (15 2558) Rx71

Case 4:

Glipizide 5 mg 2 bid, simvastatin20mg 1

1. insulin 1. 2. recombinant DNA3. 4. 5.

2. FBS HBA1C ( 9 )

1. Dosage too low2. Dosage too high3. Need additional drug4. Wrong drug5. Adverse drug reaction

3.1. insulin sensitizer2. 3. glinide4. HbA1C

4. Glibenclamide

1.

Hypoglycemia

5.

1. RI 2. Insulin NPH 3. Insulin Aspart --4. Insulin Glagine - 5.

insulin lispro

Case 5:

55 AC 5 cycle

doxorubicin 60 mg/m2 cyclophosphamide...ER+Tamoxifen

1. Cyclophosphamide

1. Hemorrhagic cystitis2. Hepatitis3. Stromatitis

4.

Hand-foot syndrome

5.

2. cyclophosphamide1. Alkylating2. Mitotic spindle3. Topoisomerase II4.

5.

3.

Doxorubicin Cyclophosphamide

Tamoxifen

5

7/24/2019 MCQ-2558 part 2

6/14

MCQ12 : 1/2558 (15 2558) Rx71

1. Doxorubicin DNA 2. Cyclophosphamide prodrug3. Tamoxifen non-steroidal antiestrogen4. Doxorubicin intercalating

DNA

5. Metabolite cyclophosphamide acrolein

4. Tamoxifen 1. 14 2. 30 3. 6

4.

1 5. 5

5. Tamoxifen1. Deep vein thrombosis2. 3. Hypertension4. Electrolyte Imbalance

5.

Dyslipidimia

6. 1. biological safety cabinet class I

class II

2. biological safety cabinet class 100-1000

3. BSC class II hepa fillter

100%4. biological safety cabinet

5.

autoclave

7. 1.

positive pressure

2.

3.

lint-free4.5.

8. tamoxifen prodrug metabolize CYP2D6 active metabolites -

1. tamoxifen fluoxetine metabolize CYP2D6 g

2. poor metabolze CYP

2D6 aromataseinhibitor

3. rapid merabolize CYP2D6

4.5.

tamoxifen

Case 6:

gout acute gout uric acid 11 mg/dl HCTZ 25 mg simvastatin 40 mg 1xhs

1.

1. 2. 3. 4. 5.

6

7/24/2019 MCQ-2558 part 2

7/14

MCQ12 : 1/2558 (15 2558) Rx71

2. gout 1. 2. Xantine oxidase3.

4.

Prostaglandin5. P glycoprotein

3. 1. Colchicine2. Allopurinol3. Probenecid4. Paracatamol

5.

Sulfapyridine

4. 1. Allopurinol2. Celecoxib3. Prednisolone4. Colchicine5. Paracetamol

5. 1. 2. 3. 4. 5.

Case 7:

Heart failure with left ventricularhypertrophy ??BP 160/105 mmHg

Furosemide 40 mg 1x1 pcEnalapril 20 mg 1x1 pc

1. Acute HF

1. 2. left ventricular hypertrophy

3.

4. 5.

2 1. Captopril2. Intravenous furosemide3. Isosorbide dinitrate SL

4.

Chewable aspirin

5. Nebulized Salbutamol

3. 1. 2. 3. 1.5 4.

5.

4. Furosemide1.

2. 1 3. 12

4.

5.

7

7/24/2019 MCQ-2558 part 2

8/14

MCQ12 : 1/2558 (15 2558) Rx71

5. 2

1. Spironolactone2. Carvedilol

3.

Captopril

4. Losartan

6. enalapril

1. Scr2. ALP3. CK

4.

bilirubin

Case 8:

GERD

1. 1. mucoprotective

2. 3. H.pylori4.

2. GERD1.

2.

3.

3. 1. 2. 3. 4. 5.

4. GERD1. Paracetamol2. Nifedipine3. Glibenclamide

4.

Amiloride

5. HCTZ

5. 1. Metoclopamide

severe maintenance therapy2. Lifestyle modification

3.

PPI H2 blockers GERD

4. prokinetic

Case 9:

1 1 ( 30

) 2-3 1 6

1. 1. acute insomnia, sleep onset and

maintainance

2. acute insommnia, sleep onset andmaintainance and wake up early

3. acute insomnia, sleep onset and wake upearly

4. chronic insomnia, sleep onset andmaintainance

5. chronic insomnia, sleep onset and wakeup early

8

7/24/2019 MCQ-2558 part 2

9/14

MCQ12 : 1/2558 (15 2558) Rx71

2. hygiene sleep 1. 2. 3.

4.

/5.

3

1. 2. 3.

4. 1. Diazepam2. Lorazepam3. Amitryptyline4. Melatonin5. Diphenhydramine

5. 1. Relaxation therapy2. light therapy3. Cognitive recognition4. Sleep and wake restriction

6. BDZs

1. halogen 7 activity

2. halogen 93. hydrolysis N 4

4.

ketone 2

Case 10:

5

1.

1.

0, 3, 7, 14,28

2. 10

3.

4. Immunoglobulin rabies

2. 1. Toxoid2. Lived atenuated vaccine3. Killed whole cell vaccine4. Subunit vaccine5. Acellular vaccine

3.

1. 2. 0 13. 0, 1 64. 4 0, 1, 6 125.

9

7/24/2019 MCQ-2558 part 2

10/14

MCQ12 : 1/2558 (15 2558) Rx71

4. 1. Equine Ig

(skin test)2. Equine Ig Human Ig

3.

Equine Ig Human Igcross

4. Equine Ig Human Ig5. Equine Ig

5.

1.

2. 3. 4.

5.

6. ERIG 1. 2. 2-8 C3. 8-15 C4. 15-25C5. 25-30 C

Case 11:

1

1. 1. Diptheria2. Viral pharyngitis3. Bacterial Tonsilitis4. Pneumocitis5.

Bacterial Sinusitis

2. 1. Hemophilus influenza2. Streptococcus pyogenes3. Corynebacterium dipteriae

4.

Morexella cathalaris

5. Staphyllococcus aureus

3. 1. 2.

3. Amoxicillin

4. Amoxicillin/Clavulanate

5. Norfloxacin

4 .??1. Rheumatic fever

2.

Influenza

3. Pneumonia4. Lung fibrous5.

3 (Influenza) Oseltamivir 0.6mg/ml sg. 30mg PO OD 10

5. Oseltamevir 1. DNA Gyrase2. Neurominidase3. Reverse transcriptase4. 5.

10

7/24/2019 MCQ-2558 part 2

11/14

MCQ12 : 1/2558 (15 2558) Rx71

6. Oseltamivie Oseltamivir Tablet 75 mg

1. 1 2. 2

3.

3 4. 4 5. 5

7. oseltamivir suspension ()

1. sorbitol

2.

alcohol3. MC4. light liquid. hard liquid.....5.

9. 1.

2.

3. 4.

5.

Case 12:

HIV HIV AZT + 3TC +lopinavir/ritonavir ergotamine +caffeine

1. HIV

1. ergotamine2. ergotamine

3.

ergotamine4. ergotamine5. ergotamine

2. 1. ergotamine naproxen sodium2. ergotamine flunarizine3. ergotamine propanolol

4.

ergotamine 5. ergotamine

3. 1. Naproxen2. Flunarizine3. Amitriptyline4. Verapamil

5.

Atenolol

.4. ergotamine

1. 10 2. 3 3. 6 /4.

5.

5. ergotamine

1. angina-like pain2. weakness leg3. hypotension4. numbness

5.

11

7/24/2019 MCQ-2558 part 2

12/14

MCQ12 : 1/2558 (15 2558) Rx71

:

1. COA xxxx lot xxx

xxx xxx

Apperance

White powder

containing in

blue capsule

Identification

Assay %LA 90-120 94%

Average Weight

?555-625? 550

Weight Variation +/- 7.5% 5%

Dissolution NLT 80% (Q) 88%

% Water NMT 5% 4%

1.

Dissolution

2. Uniformity of Dosage Unit3. Weight Variation4. Water5. Assay 550

555-625

2. Tiotopium Vd = 36 L/kg Bioavailability =

20% T1/2 = 5 50 kg 18 mcg iv bolus

1. 2 ng/L2. 5 ng/L3. 1 ng/L4. 10 ng/L

5.

20 ng/L

3. Residual on Ignition 1. organic2. inorganic3. inorganic

4.

5.

4. Dissolutionmonograph Q = 80%Interpret Dissolution

1. Stage 2:

12 1 65%

2. Stage 2: 12 65% 80%

3. Stage 1: 6 1 85%

4.

Stage 1:

6 1 85%

5. Stage 1:

5. 1-100normal distribution

1. U man-whitney2. Pair t-test3. Independent t-test4. Multiple linear regression5. Cox proportional hazard ratio

12

7/24/2019 MCQ-2558 part 2

13/14

MCQ12 : 1/2558 (15 2558) Rx71

6. 1. acetylcysteine

2.

ascorbic acid3. Sodium bicarbonate4. pyridoxine5. phenzopyridine

8. CL 1. 2.

3. 4. 5.

9. 1.

2. 3. 4. 5.

10. Monograph Glipizide Tablets? Identification

1. GC2. HPLC

3.

TLC

4. HPLC and TLC5. GC HPLC

11. modify

1.

halogen 92. halogen 73. ring A heterocyclic ring4. 4 5. C=O C=N

12. regimen Cost mionimization

analysis (CMA) 1. 10 1 4 5

2. 15 1 3 5

3. 20 1 2 7

4. 30 1 1

7 5. 40 4

13

7/24/2019 MCQ-2558 part 2

14/14

MCQ12 : 1/2558 (15 2558) Rx71

13. recall 1. Recall 2. 3.

4.

5. SOP

14. preservative 1. benzyl alcohol2. disodium sulfate

15. 1. 2. 3.

16.

1. alu-alu2. blister3. foil4. strip5. sachet

17. statin gemfibrozil

1.

18. statin Gemfibrozil

1. CYP 3A42. CYP 2C93. Glucorination4. enzyme carbonic anhydrase

5.

OATP1B1

19.

1.

2.

3.

4.

5.

14